All issues
Volume 55, Issue 12
Displaying 1-10 of 10 articles from this issue
- |<
- <
- 1
- >
- >|
Picture in Clinical Hematology
-
[in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...2014 Volume 55 Issue 12 Pages 2379
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSDownload PDF (1488K)
Review
-
Mio KURATA, Atsumi YANAGISAWA, Yoshiko ATSUTA, Hisashi SAKAMAKI, Koji ...2014 Volume 55 Issue 12 Pages 2381-2399
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESS
Clinical Study
-
Yasuyuki ARAI, Tadakazu KONDO, Toshiyuki KITANO, Masakatsu HISHIZAWA, ...2014 Volume 55 Issue 12 Pages 2400-2407
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSGastro-intestinal cytomegalovirus infection (GI-CMV), which occurs after allogeneic stem cell transplantation (allo-SCT), is diagnosed by immunostaining of biopsied tissues obtained using a fiberscope. However, the sensitivity of this pathological diagnostic test is poor. We evaluated the suitability of using quantitative polymerase chain reaction (qPCR) to test GI-mucosal tissues for CMV. We analyzed adult patients who had undergone allo-SCT at our institute. Twentyseven specimens were collected from patients undergoing GI-fiberscopy for upper GI-symptoms after allo-SCT. Of these patients, 9 tested positive for CMV by qPCR; their symptoms resolved soon after receiving antiviral therapies for CMV. Pathological procedures detected GI-CMV in only 3 cases. In contrast, CMV qPCR was positive for 12 of 30 specimens collected from patients with lower GI-symptoms by using colon fiberscopy. Antiviral therapies were effective in all but one case. GI-CMV was diagnosed pathologically in only 5 cases. Therefore, CMV qPCR is effective for early therapeutic intervention in CMV-GI patients after allo-SCT.View full abstractDownload PDF (782K)
Case Reports
-
Yasuyuki KUNIEDA, Satomi MATSUOKA, Misato KIKUCHI, Naoki KAWAMURA, Shi ...2014 Volume 55 Issue 12 Pages 2408-2413
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSA 79-year-old man received gastrointestinal endoscopy for reexamination of a gastric submucosal tumor in May 2002 and whitish granular mucosa was found near the ampulla of Vater of the duodenum, though biopsy specimens showed only lymphocyte infiltrations. In December 2002, a second gastrointestinal endoscopy revealed an irregular granular elevated lesion around the ampulla of Vater and biopsy specimens showed pathological findings of follicular lymphoma. No other abnormal findings raising suspicion of tumor formation were observed on systemic examinations and the diagnosis of duodenal follicular lymphoma was confirmed. Systemic chemotherapy using rituximab at 375 mg/m2 weekly for 4 consecutive weeks was started in January 2003. Six months later, endoscopic findings of the lesions revealed nearly normal mucosa around the ampulla of Vater, though histologically the biopsy specimens showed residual lymphoma cells. The same rituximab therapy as before was started in November. There has been no evidence of recurrence and a prolonged, more than 10 years, complete remission has been achieved.View full abstractDownload PDF (7614K) -
Hina TAKANO, Kaoru NAGATA, Daisuke WANABE, Manabu OHKI, Atsushi KATO2014 Volume 55 Issue 12 Pages 2414-2417
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSA 72-year-old female was diagnosed with chronic phase chronic myeloid leukemia (CML) in 2001. After a short course of treatment with hydroxycarbamide, imatinib (IM) 400 mg was started. A major molecular response was presumably acquired 10 months later. IM was discontinued after treatment for 47 months in November 2005. At the same time, BCR-ABL transcript was undetectable by nested RT-PCR assay, which was equivalent to <0.00138% BCR-ABL according to the international scale. The patient is still under observation with no additional therapy, and BCR-ABL has remained negative for 102 months, to date. Furthermore, interferon was never used in this patient. IM has dramatically improved the prognosis of CML. Since no cure has yet been established, patients are recommended to continue treatment even after achieving deep molecular responses. There are several ongoing clinical trials challenging the discontinuation of IM, but long-term observation is still lacking. The sustained deep molecular response, exceeding eight years, experienced in this patient is potentially encouraging.View full abstractDownload PDF (678K) -
Kagehiro KOUZUKI, Itaru KATO, Takeo KATO, Tomoo DAIFU, Satoshi SAIDA, ...2014 Volume 55 Issue 12 Pages 2418-2422
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSThe incidence of HHV-6 encephalitis during hematopoietic stem cell transplantation (HSCT) in children is thought to be less than that in adults and risk factors, prognosis and complications are virtually unknown. Herein, we report a pediatric case developing epileptic encephalopathy following HHV-6 encephalitis after a second cord blood transplantation (CBT). A 7-year-old boy with relapsed B-precursor acute lymphoblastic leukemia in second remission underwent CBT. However, he received a second CBT due to graft failure. On day 25 after the second CBT, he developed short-term memory defects and seizures. He was diagnosed with HHV-6 encephalitis because HHV-6 DNA was detected in his blood and cerebrospinal fluid and abnormal hippocampal signals were seen on cranial magnetic resonance imaging (MRI). After treatment with foscarnet, HHV-6 DNA levels and MRI findings improved; however, he developed epileptic encephalopathy five months after the onset of encephalitis. There are very few reports on pediatric epileptic encephalopathy associated with HHV-6 encephalitis after HSCT. Detailed studies are needed to analyze risk factors, prognosis, and complications.View full abstractDownload PDF (2232K) -
Keiki NAGAHARU, Kana MIYAZAMI, Hiroshi IMAI, Asako TAMURA, Akira UMINO ...2014 Volume 55 Issue 12 Pages 2423-2428
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSBing-Neel syndrome is known as Waldenström's macroglobulinemia with central nervous system infiltration by neoplastic lymphoplasmacytoid and plasma cells. A 74-year-old man was admitted because of progressive cognitive impairment. Serum immunoelectrophoresis showed a monoclonal IgM-kappa component. Bone marrow aspiration revealed 59% small lymphocytes showing plasmacytoid differentiation. Bone marrow flow cytometry disclosed a population of kappa light-chain positive lymphoid cells expressing CD19, CD20, CD38, and CD138. Magnetic resonance imaging of the brain demonstrated gadolinium-enhancement in the right temporo-parieto-occipital meninges with sulcal enhancement. Cerebrospinal fluid cytology showed a population of lymphoplasmacytoid cells, positive for CD19, CD20, CD25, and kappa light-chain. Based on these findings, Bing-Neel syndrome was diagnosed. Although combination chemotherapy consisting of intrathecal methotrexate and oral cyclophosphamide was started, his symptoms continued to worsen. Then, we initiated treatment with a regimen consisting of fludarabine/rituximab (FR). After 6 courses of this FR regimen, a complete remission was achieved. Our case suggests the FR regimen to potentially be an effective treatment option for Bing-Neel syndrome of the scattered type.View full abstractDownload PDF (2476K)
Short Reports
-
Hideki HATTORI, Maki KUWAYAMA, Hiroyuki TAKAMORI, Nobuko NISHIURA, Tak ...2014 Volume 55 Issue 12 Pages 2429-2432
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSWe report a 77-year-old Japanese man with idiopathic thrombocytopenic purpura (ITP) which developed into chronic myelogenous leukemia (CML) during treatment with eltrombopag, a thrombopoetin (TPO) receptor agonist, because the disease was refractory to prednisolone. Eltrombopag can induce a good reaction in terms of the platelet count. However, CML in the chronic phase developed in about 19 months in our present case. Dasatinib was administered because he had diabetes. However, a blastic crisis immediately occurred. He died despite switching to Nilotinib. Recently, the occurrence of myelofibrosis and hematological malignancies due to long-term use of TPO receptor agonists has become a concern. This is the first report of a TPO receptor agonist possibly contributing to CML onset and crisis.View full abstractDownload PDF (2291K) -
Masaru TANAKA, Naoki WATANABE, Yasuo AOTA, Jun ANDO, Akihiko GOTOH, No ...2014 Volume 55 Issue 12 Pages 2433-2436
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSA 78-year-old man with liver cirrhosis was admitted to our hospital because of persistent diarrhea and abdominal pain. Colonoscopy revealed erosions and submucosal tumors in portions of the sigmoid colon and rectum, which were diagnosed as mantle cell lymphoma with biopsy. After chemotherapy consisting of vincristine and prednisone, he developed Aeromonas hydrophila septicemia, resulting in septic shock and necrotizing fasciitis despite prescribing antimicrobial agents to which this organism was susceptible. Whenever we intend to treat patients with hematological malignancies and an underlying chronic liver disease, we must keep this bacterium in mind.View full abstractDownload PDF (722K)
Introduce My Article
-
2014 Volume 55 Issue 12 Pages 2437-2438
Published: 2014
Released on J-STAGE: January 07, 2015
JOURNAL RESTRICTED ACCESSDownload PDF (612K)
- |<
- <
- 1
- >
- >|